1.
Journal of the Japanese Association for Infectious Diseases
; 96(5):179-185, 2022.
Article
in Japanese
| GIM | ID: covidwho-2203546
ABSTRACT
Background: Randomized phase III clinical trials suggest that the antibody cocktail containing casirivimab and imdevimab reduces the risk of hospitalization/death in high-risk COVID-19 patients. However, the efficacy of the cocktail in daily clinical practice remains unknown.